Fisher & Paykel Healthcare Hosts Investor Day in Sydney

Stock Exchange Announcement
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare Hosts Investor Day in Sydney

Auckland, New Zealand, 16 October 2017 - Fisher & Paykel Healthcare Corporation Limited
(NZX:FPH, ASX:FPH) is hosting a product and clinical overview for analysts and investors in
Sydney today.

The presentation is attached and will also be made available on the company’s website at
www.fphcare.com/investor/presentations.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep
apnea. The company’s products are sold in over 120 countries worldwide. For more information
about the company, visit our website www.fphcare.com
.

Ends

Contact:
Investors:
Marcus Driller
General Manager Corporate
marcus.driller@fphcare.co.nz
+64 (0) 27 578 9663
Media:
Rachel Reynolds
Senior Communications Manager
rachel.reynolds@fphcare.co.nz
+64 (0) 21 713 911

---

Care by Design
Fisher & Paykel Healthcare Investor Day
Sydney, October 2017

Morning Agenda
10:00amWelcomeMarcusDrillerGeneral Manager Corporate
10:00amSustainable Profitable GrowthLewis Gradon Managing Director & CEO
10:15amPatient-focused R&DAndrew Somervell VP - Products & Technology
10:35amSales Approach: EnablingClinical ChangePaul Shearer Senior VP - Sales & Marketing
10:55amAirvo & Optiflow: World-LeadingTechnologyChris Crone Airvo R&D Manager
11:15amTransformingRespiratory Therapy
in Infant Care
Andy Niccol General Manager -Infant Care
11:35amNasal High Flow
The Brisbane (Paediatric) Experience
Dr Andreas SchiblerLady CilentoChildren’s
Hospital
12:00pm - 1:00pm Lunch Break
Time will be made available at the end of each presentation specifically for questions and answers.
SUSTAINABLE PROFITABLE GROWTH
GLOBAL REACH
CHANGE CLINICAL PRACTICE
BETTER PRODUCTS

SUSTAINABLE PROFITABLE GROWTH
GLOBAL REACH
CHANGE CLINICAL PRACTICE
BETTER PRODUCTS
Afternoon Agenda
1:00pmBuilding the body of clinical evidencefor
myAirvo and Optiflow in the home
Chris CroneAIRVO R&D Manager
1:10pmNasal highflow humidified air via
hospital in the home
Dr Darren MansfieldMonash Health
1:30pmDriving Patient Success with OSA TherapyFiona CresswellGeneral Manager Marketing
2:00pmManagementTeam Q&ALewis Gradon
Paul Shearer
To n yBarclay
Debra Lumsden
Andrew Somervell
Winston Fong
Managing Director & CEO
Senior VP – Sales & Marketing
Chief Financial Officer
VP – Human Resources
VP – Products & Technology
VP – Surgical Technologies
2:25pmClosing CommentsLewis GradonManaging Director & CEO
2:30pm – 3:00pm Product hands-on and further opportunity to speak with FPH team
Time will be made available at the end of each presentation specifically for questions and answers.

Sustainable
Profitable
Growth
Lewis Gradon
Managing Director & CEO

Question most often asked by investors
How long can you continue to grow
at these kind of rates?
NET PROFIT AFTER TAX NZ$MILLIONS
OPERATING REVENUE NZ$MILLIONS
5 YEAR CAGR = 12%
5 YEAR CAGR = 21%

We’ve established
an enviable
track record
for delivering
SUSTAINABLE
REVENUE
GROWTH.

Where will
sustainable
growth come
from in the
SHORT-TERM?

Where will
sustainable
growth come
from in the
MEDIUM-TERM?

Where will
sustainable
growth come
from in the
LONGER-TERM?

OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.

Characteristics of our business
GROWTH PROFITABLY, SUSTAINABLY
Marketopportunities
•Diverse, growing clinical data
•Underpinned by favourable
demographics, aging populations and
developing country healthcare spend
Valued customer benefits
•Improved patient outcomes
•Lower cost of care
Independence of economic cycles
•Revenue derived from treating a patient
Barriers to entry
•Regulated
•Patented IP
•Care Continuum: Throughout hospital to
home
•Sales force investment
•Knowledge base
Relatively predictable cash generation
•Hardware placement drives per patient
consumables
•Successful treatment resists change
•Change of clinical practice inertia

Questions?

Patient-focused
R&D
Andrew Somervell – Vice President
Products and Technology

Improving Clinical Practice: R&D approach
•Unique products with valued differentiation
that:
−Improve care and outcomes
−Lower overall cost of treating patients
• Proven innovation history
• Original thought required
• Enabled through understanding unmet
patient and caregivers’ needs

Patient Oriented R&D
•Philosophy of doing what’s best for the patient
−Needs of all stakeholders align with
patient needs
−Encourages long term thinking
−Ingrained in FPH culture
•Patient focused multi-disciplinary product
teams
−Specialist skills, broad knowledge

Patient Focused Teams: In-depth Knowledge
NEW IDEAS, ORIGINAL THOUGHT
Physiology
Environment
Users
Adjacencies
Key Opinion Leaders
Clinical Research
Technology
Competitors

Enabling our Product Teams
•Easy access to the user environment:
−Strong relationships with local and offshore
hospitals and homecare dealers
−Patient knowledge, testing solutions
•Learning by creating
−Prototype, test, learn
−World-class prototyping and testing facilities
•Access to world-leading technology experts
•R&D access to manufacturing
•Proven ability to attract and grow top talent

F&P 950: Redefining Expectations
•F&P 850 current market leader

AirSpiralInspiratory Limb
•Opportunity:
−Optimal humidity, minimal condensation in difficult
ambient conditions
•Benefits:
−Reduce ventilation breaks
−Reduce infection risk
−Reduce clinician’s time dealing with condensate
•Idea:
−Insulate delivered medical gas with pockets of air
•Result:
−AirSpiralTube
•Technical challenge
−How to manufacture
•Conceived for 950, adapted for Airvo and SleepStyle

Questions?

Sales approach:
enabling clinical
change
Paul Shearer
Senior VP –Sales & Marketing

Clinical change process

Developing sales team effectiveness
•Product training
•Therapy understanding
•Expert domain knowledge
•Develop customer relationships
•Trusted advisor
Takes several years for a FPH sales rep to become fully effective
EconomicsEvaluation
Therapy/
clinical
Marketing
Sales
force
knowledge
SalesAdoptionProducts

Role of marketing
•Condition market for sales organisation
•Patient group experts
•Develop messaging and approach
•Clinically-focused marketing
•Promote FPH brand
•Product approval and country
registrations
EconomicsEvaluation
Therapy/
clinical
Marketing
Sales
force
knowledge
SalesAdoptionProducts

Clinical and therapy validation
•Develop Key Opinion Leaders
(KOL relationships)
•Pilot studies
•Physiological studies (Mechanisms)
•Outcome studies (RCT)
•Peer to peer education
EconomicsEvaluation
Therapy/
clinical
Marketing
Sales
force
knowledge
SalesAdoptionProducts

Value-based economics
•Cost calculators
•Translation of clinical evidence to financial
benefits
•User case studies
•External financial validation
•Reimbursement / payment pathways
EconomicsEvaluation
Therapy/
clinical
Marketing
Sales
force
knowledge
SalesAdoptionProducts

Evaluation
•Customer preparedness
•Evaluation criteria
•Educating clinicians over multiple shifts
•Validating critical success factors
•Trust and confidence
EconomicsEvaluation
Therapy/
clinical
Marketing
Sales
force
knowledge
SalesAdoptionProducts

Sales achievement
•Contract (GPO / IDN) formularies
•Win / meet tender specifications
•Capital acquisition (annual cycles)
•Lease / commitment programmes
•Installation / in-service support
•Customer success
EconomicsEvaluation
Therapy/
clinical
Marketing
Sales
force
knowledge
SalesAdoptionProducts

Driving adoption
•Facilitate change management
•Customer commitment
•Standard of care
•Physician-generated protocol
•Product performance
•Ongoing review
EconomicsEvaluation
Therapy/
clinical
Marketing
Sales
force
knowledge
SalesAdoptionProducts

Customer satisfaction
•Proven product performance 
•Improved care and outcomes based on unique FPH product 
•Strong relationships and trust 
•Product standardisation and continuum of care 
•Customer commitment 

Enabling clinical change -summary
•Clinical change is a disruptive, lengthy
and complex process
•Clinicians:
working with trusted products delivering
improved outcomes
to at risk patients
are reluctant to change

Questions?

Airvo& Optiflow:
World-Leading
Technology
Chris Crone
Research & Development Manager –
Airvo/Optiflow

What is Optiflow nasal high flow therapy?
CONVENTIONAL
OXYGEN THERAPY
NON-INVASIVE
VENTILATION

0
20
40
60
80
100
120
140
160
180
200020022004200620082010201220142016
AdultNeonatal & Paediatric
Interest accelerating in Nasal High Flow therapy
NasalHighFlow
ClinicalPapers
Published
Annually

2014-2015: Breakthrough publications

2016: More evidence post-extubation
Summary
-3 centres in Spain
-604 patients at highrisk of reintubation
-Optiflow was non-inferior to NIV
-7 centres in Spain
-527 patients at lowrisk of reintubation
-Optiflow significantly reduced
reintubation rates vs O2
Summary
Reintubation is linked with poor outcomes

Emerging evidence in other areas
•Hypercapnicpatients
−Large randomised controlled trials (RCTs) in
planning stages (French government support)
•Emergency department
−Bell, et al. 2015. Emergency Medicine
Australasia
−Makdee, et al. 2017. Annals of Emergency
Medicine
•Wards
−Pirret, et al. 2017. Intensive Critical Care
Nursing

Emerging evidence in other areas
•Evolution in research
−Different patient groups and settings
−Larger trials
•Towards:
−All spontaneously breathing patients
requiring respiratory support

FPH technology advantage
For Optiflow Nasal High Flow:
•Generatingwith Airvo
•Transportingwith AirSpiral
•Deliveringwith Optiflow
Generating
Transporting
Delivering

Generating with Airvo
Superiority in:
•Performance - humidification, flow, sensing
•Versatility – wide range of temperatures, flows and oxygen
•Mobility – throughout the hospital
Transporting
DeliveringGenerating

Transporting with AirSpiral
•Superior protection against condensate
•Patents filed on technology and processes
Delivering
Transporting
Generating

Delivering with Optiflow
•The only interface with Evaqua technology
•Reduces formation of mobile condensate
•Comfort for patients and confidence for clinicians
Delivering
Generating
TransportingDelivering

Exciting potential
•Huge clinical interest in Optiflow
•We are well-positioned with Airvo,
AirSpiraland Optiflow technologies

Questions?

Transforming
Respiratory Therapy
in Infant Care
Andy Niccol
General Manager –Infant Care

Infant care continuum

Current evidence supporting the clinical applications of NHF

The next generation of care

Enhanced prong retention

Enhanced prong retention

Wider range of sizes

Retains existing product benefits

Wigglepads

Tube Technology

Questions?

---

Associate Professor Andreas Schibler
Paediatric Intensive Care Staff Specialist FCICM - PICU
Medical Lead of Paediatric Critical Care Research Group (PCCRG)
Lady Cilento Children's Hospital and The University of Queensland
Nasal High Flow
The Brisbane (Paediatric) Experience
The PCCRG receives an ongoing research grant from
Fisher & Paykel Healthcare. Travel expenses associated with this
presentation have been covered by Fisher & Paykel Healthcare

2016: Current intubation rate <3%

•83 general paediatricdepartments (peripheral/secondary/tertiary)
•7/8 tertiary, 5/6 secondary and 38/69 peripheral response
•45/49 use HFNC: 91%
7
14
25
30
38
45
0
5
10
15
20
25
30
35
40
45
50
201020112012201320142015
Number of departments using
HFNC (of 49 total)
84
100
88
51
31
0
20
40
60
80
100
120
0-4 weeks1-12 months12-24 months2-5 years6-16 years
percentage used per age group
(of 49 total)
Survey of NHF therapy use in Australia

Diagnostic groups
• 100% of departments use it for bronchiolitis
• 82% in pneumonia
• 55% in reactive airways (asthma)
• 40% in other respiratory disease
Survey of NHF therapy use in Australia

• Can be applied very early in the
disease process
• Greater patient tolerance
• Ease of application
• Clinical effectiveness
Other benefits of NHF therapy

What are the trials we need to do?
• RCT in infants with bronchiolitis
• RCT in infants and children with Acute Hypoxic Respiratory
Failure:
- Pneumonia
- Pneumonitis
- Reactive Airway Disease (Asthma)
When, Where and How?
•Start in ED ? Early ?
•Start only if admitted ?
•Start only if certain severity threshold is achieved?

PARIS 1 Background
Burden of Bronchiolitis
•Highest number of non-elective PICU admissions in 2015 (19%).
•Low mortality (~0%)
•Median PICU LOS 3.08 days
•Currently ANZPIC data registry showing higher figures for bronchiolitis
admitted to ICU. Compatible with USA data which is also increasing. Is this
due to NHF being used in some centres in ICU only?
•USA cost burden – US$1.7B/annum (Hagaswasa)
Should NHF therapy be used outside of ICU??

Ye a r
Mechanical
VentilationIntubation
Non-Invasive
VentilationNHF therapy
200257.2%36.6%30.5%
200353.9%30.9%35.0%
200457.4%29.2%42.6%
200556.8%29.5%42.4%
200660.5%26.9%47.5%
200762.8%26.5%49.7%
200853.2%23.5%40.9%
200963.4%25.9%46.8%
201058.6%24.5%42.2%24.7%
201162.0%16.6%59.3%35.8%
201258.1%20.1%44.7%54.7%
201346.6%12.6%38.5%71.2%
201444.8%10.8%38.2%72.6%

Modes of Respiratory Support
in PICU for Bronchiolitis

Health care costs associated with
Bronchiolitis infants admitted to ICU

NHF
introduction

NHF =
Everybody
Loves it

NHF
Everybody
is over it

NHF
Introduced in Paeds Ward

NHF
Reducing ICU admission

PARIS I – Nasal High Flow therapy in infants with
bronchiolitis – a Randomised Controlled Trial
AIM
To compare in a Randomised Controlled Trial, Nasal High Flow therapy
to standard oxygen delivery in infants with bronchiolitis, presenting to
regional, metropolitan and tertiary centres.
PRIMARY OUTCOME
Defined as treatment failure of NHF therapy or standard oxygen therapy.
INCLUSION CRITERIA
•Infants < 12 months of age
•Diagnosis of bronchiolitis
•Oxygen requirement (SpO2 <92% in room air)
SAMPLE SIZE: 1400

To measure:
• reduction in the need for retrievals/ICU admission
• reduction in intubation rate
• reduction in LOS
• length of oxygen therapy
• adverse effects
• health care costs
• study effect of room air only?
Secondary Outcomes

Recruitment over 3 years – 1400 patients
•Nine Regional Hospitals
•Ipswich Hospital
•TPCH
•RedcliffeHospital
•Redland Hospital
•CabooltureHospital
•Logan Hospital
•NambourHospital
•Toowoomba Hospital
•The Tweed Hospital
•LCCH
•GCUH
•RCH – Melbourne
•Monash – Melbourne
•Canberra Hospital
•Townsville Hospital
•Starship – Auckland NZ
•KidzFirst, Middlemore – NZ
Additional PREDICT sites with NHMRC funding

Study Protocol
n=1400
$1.3 M NHMRC funding
Inclusion Criteria
* Bronchiolitis
* SpO2 <92/94%%
* < 12mths
NHF
2L/kg/min
Control
Responder
NHF
2L/kg/min
Non-Responder
Non-Responder
Responder
Transfer
Non-Responder
Responder
Transfer
Criteria for non-responder:
RR, HR and EWT unchanged after 120-180 min
Primary
Outcome

Standard
Oxygen
Nasal High
Flow
SexN=731N=745
Male469 (64%)455 (61%)
female261 (36%)287 (39%)
Median agemonths (IQR)
6.1 (3.4)
months (IQR)
5.8 (3.5)
Age
≤3 month185 (25%)207 (28%)
3-12 months546 (75%)538 (72%)
Prematurity107 (15%)127 (17%)
Weight (kg) (SD)7.6 (2.2)7.3 (2.3)
Virus detected
RSV positive321 (44%)335 (45%)
Baseline Characteristics

Standard
Oxygen
Nasal High
Flow
P valueOdds ratio
N=731N=745
Failure Rate16789
#
0.00012.20 (1.65-2.89)
% of patients23%12%
Non-
responders/Responders
<3month of age
55/13028/179
#
0.00012.71 (1.63-4.50)
Non-
responders/Responders
3-12 months of age
112/43461/477
#
0.00012.02 (1.44-2.83)
Length of O2 therapy
(median)
days (IQR)days (IQR)
All infants
1.23
(1.82)
1.24 (1.81)
*
0.218
All infants without ICU
admission
1.13
(1.54)
1.07 (1.51)
*
0.025
Primary Outcomes

• 6.3 million children < 5yrs died worldwide in 2013 (WHO)
1 million of these deaths -caused by resp infections
• AHRF - most frequent reason for paeds admission
Most common initial treatment is to offer 02
• Approx 20% of children with AHRF rapidly deteriorate and
require assisted breathing with positive pressure or mechanical
ventilation (PICU)
• Very little evidence in children with AHRF
AHRF BACKGROUND

AIM
To compare in a Randomised Controlled Trial, Nasal High Flow therapy
to standard oxygen delivery in infants and children with Acute Hypoxemic
Respiratory Failure (AHRF), presenting to regional, metropolitan and
tertiary centres.
PRIMARY OUTCOME
Defined as treatment failure of NHF therapy or standard oxygen therapy.
INCLUSION CRITERIA
•Infants and children 0-16 yrs of age
•Diagnosis of AHRF and admitted to hospital
•Oxygen requirement (SpO2 <92% in room air)
SAMPLE SIZE: 610
PARIS II
Nasal High Flow therapy in children with Acute
Respiratory Failure – a Randomised Controlled Trial

To determine if use of NHF therapy reduces the need for
hospital transfer to a tertiary centre
To determine if there is an age dependent efficacy of NHF
therapy
To perform Subgroup Analysis for children with:
eg. RAD (asthma), Bronchiolitis 12-24mths, Acute Lower
Resp. Tract Infection
Secondary Outcomes

• Bias (creep in effect)
• If NHF therapy has been used prior in a centre
(stronger bias present)
• Adherence to protocol by medical staff – change in
diagnosis to place child on NHF (bias) Consent
Research culture present or not
• Study Fatigue (PARIS 2 with dual trials)
CHALLENGES PARIS 1 & 2 –Study specific

THANK YOU

myAirvo Research
Update
Chris Crone
Research & Development Manager –
Airvo/Optiflow

Nasal High Flow -Acute vs. Chronic use
Chronic
•Same therapy, different uses, different benefits
Acute

Home-based clinical research
•More research being carried out in the home
•Challenges
−Patient group –age, care needs
−Logistics
−Compliance monitoring
−Longer treatment times (1 year : 5 years)
−Higher costs

Mechanisms research
273sleep studies in the
FPH sleep lab
Over
400
participants
completed
development
trials
Author JournalYrnPopulationComparisonF/upEffects
Hasani
ChronRespDis 2008
10BronchiectasisNHF vs no NHF7d
↑Increased Mucociliaryclearance
Fraser
Thorax2016
10COPDNHF vs O
2
<1d
↓Reduced CO
2
(measured through skin)
↓ReducedRespiratoryRate
↑Increased Tidal Volume
Bräunlich
J COPD 2016
48COPDNHF vs O
2
<1d
↓Reduced CO
2
(measured through skin)
↓ReducedRespiratoryRate
↑Increased Tidal Volume
Biselli
J ApplPhysiol2016
18COPDNHF vs O
2
<1d
↓Reduced CO
2
(measured through skin)
↓ReducedWork of Breathing
↓ReducedMinute ventilation
Pisani
Thorax2017
14HypercapnicCOPDO
2
vs NHFO
2
and
NIV
<1d
↓ReducedRespiratoryRate
↑Increased Tidal Volume
↓ReducedCO
2
(blood gas)
Pilcher
Respirology2017
24AECOPDNHF vs O
2
<1d
↓ReducedCO
2
(blood gas)
McKinstry
Respirology2017
48COPDNHF vs breathing<1d
↓Reduced CO
2
(measured through skin)
↓ReducedRespiratoryRate

Outcomes research
Author JournalYrnPopulationComparisonF/upMessage
Rea
RespMed 2010
108COPD&
Bronchiectasis
NHF (w and w/o
O
2
) vsSC
1yImprovedexacerbation days, time to 1
st
exacerbation, reduced antibiotic use
Cirio
RespMed 2016
12COPD in
Pulmonary Rehab
NHFO
2
vs Venturi
O
2
<1dImprovedexercise tolerance
Macann
IntJ RadiationOncolBiolPhys
2010
210Head& Neck
Cancer patients
with mucositis
NHF vs Usual
care
12wImprovedpatient functioning, nutritional
events, decreased number of inpatient
days
McNamara
RespCare 2014
15TracheostomyTHF vs HME10wLongterm: reduced adverse events

COPD research underway
PI, CountrynPopulationComparisonF/upPrimary Outcome
Weinreich, Denmark200COPDNHFO
2
vs O
2
1yExacerbations & hospital admissions
Mansfield, Australia150COPDNHF vs no NHF30dLength ofStay,30 dreadmission
Bräunlich, Germany100COPDNHF vs Bilevel6wCapillary CO
2
Nilius, Germany 40COPDNHFO
2
vs O
2
1yOvernight trans. CO
2
Chihara, Japan32COPD w CRFNHFO
2
vs O
2
4w6 Min. Walk Distance
Tomii, Japan30COPDNHFO
2
vs O
2
6wQuality of Life (St Georges Resp.Quest.)
Allen, USA30COPDNHF(O
2
) vs Usual3mQuality of Life (Breathless,Cough Sputum Scale)
Fernandes, USA30COPDNHFO
2
vs O
2
1yHospitalizations
Bräunlich, Germany20COPDNHF Neb vs Neb< 1dLung Function (FEV
1
)
Criner, USA10Unstable COPDNHF5 dAbility to maintain SpO
2
> 90%
Criner, USA30COPDNHF90 dCompliance

A bright outlook
•There are challenges to home-based
research
•Studies are underway with myAirvoand
early results are promising

Questions?

NASAL HIGH FLOW HUMIDIFIED AIR VIA HOSPITAL IN THE HOME
A/PROF DARREN MANSFIELD
MONASH HEALTH
HOSPITALIZED COPD
EXACERBATIONS:

DISCLOSURE
•A/Prof Mansfield has received research funding from Fisher & Paykel
Healthcare.
•Fisher &Paykel Healthcare will make a donation to the Monash Lung
and Sleep Institute and Assoc Prof Mansfield will be reimbursed for any
expenses incurred in connection with his participation in today’s
event.

THE BURDEN OF DISEASE ON THE ACUTE FACILITY
•COPD exacerbations Dandenong Hospital
•90% are admitted to hospital
•No/yr
•LOS 5.9 days
•60 day readmission rate 22%
Large numbers due to comorbidities and social circumstancesrather
than severe acute exacerbations

CHARACTERISTICS
FLOW RATES -60L/MIN
TEMPERATURES 37 DEGREES
LOOSE FITTING CANNULA

POSTULATED BENEFITS
•Facilitative effects
•Staff
•Patients
•Clinical/Physiological Effects

PRELIMINARY NUMBERS
•Admissions under Hospital In The Home (HITH) = 20
•Readmissions post discharge from HITH = 1
•Patients who purchased AIRVO system privately = 2
•Good outcomes in patient satisfaction with care &
symptom improvement while on NHF

SUMMARY
•Can realistically be incorporated into an acute clinical management
setting
•Reduces hospital length of stay, inpatient complications and recurrent
admissions
•Beneficial not only to patients
•Can assist in unloading the healthcare system

Thank you

Driving Patient
Success with
OSA Therapy
Fiona Cresswell
General Manager Marketing

Unique and Personal

The Threat
•Up to 100M OSA sufferers
1,2
•CPAP therapy is the gold standard
of treatment
•Up to 50% will abandon therapy,
many within first 2 weeks
•Untreated sleep apnea has many
life threatening consequences
1. Chronic disease epidemics. World Health Organization website. May 23, 2012. 2. Peppard, PE et al, American Journal of
Epidemiology (2013): National Center for Biotechnology Information. U.S. National Library of Medicine

Main Drivers of Non-Adherence
1. Bollig, S.M. RespirCare, 2010. 55(9): pp. 1230-92. Aljasmi, M., et al. J Sleep Med Disord, 2016. 3(2): 1044
•Leaks
1
•Facial Abrasions
1
•Mask Discomfort
1,2
•Claustrophobia
1,2

Intimacy of the Mask
•Comfort
•Seal
•Ease of Use
= CONFIDENCE

User Experience Mask Design Philosophy
Perception
Education
Fitting
PerceptionFitting
Seal
Disassembly
Cleaning
Confident
ongoing use
Patient
Equipment
Provider
Part identification
& Resupply
Reassembly
Eliminates need
for support

Complex and Diverse Facial Anatomy

Our Leading-Edge Masks

AirPillowSeal

We Measure What Nature Created
•Facial Scanning
−Many hundreds of real OSA participants
−200,000+ points captured
•Anthropometric Database
−42 key facial dimensions
−Statistically analysed
−Numerically driven seal design

We Use Technology to Optimise Design
•3D CAD Modelling
‒Gradient transitions
‒Integrated mask stabilizers
•Massive Variable Thickness Moldings
‒1200% range in single molded part
‒Satin surface finish

The Benefit
•Soft Nasal Prongs
‒1/33 inch (0.75mm) thickness (1)
‒Gently contours to nostril shape
‒Significantly less pressure on the septum
•Super Thin Silicone Seal Membrane
‒Prongs surrounded by thin silicone
‒1/100 inch (0.25mm) thickness (2)
‒Allows prong rotation in any direction
1
2

Adjustable Headgear
Provides stability
against dislodgement
Tactile Feedback and
locks in place
Adjustable to offer
personalised secure fit

We Consider Real World Use
•Lifecycle Testing
‒Soaked in sweat solution
‒Cleaned over 50 times
‒Stretched 2800 times
•Destruction Testing
‒Pulled until broken
‒Target = 30N Force

Washable Exhaust Diffuser

We Quantify the Invisible
•Sound Testing
‒Target less than 25dBA
•Draft Testing
Anechoic Chamber

We Amplify Accuracy Using Technology
•Computational Fluid Dynamics
‒Map airflow
‒Highlight turbulence
‒Optimisedesign
•Optical Gauge Smartscope
‒Accuracy of 1.4μm

The Benefit
•Reduced air flow disruption
•Sound reduction -1 7. 5 d B
‒similar to a ticking watch

Visiblue
•Blue Highlights incorporated into
key components
•Supports mask education,
orientation and reassembly

F&P SleepStyle
CPAP/Auto Therapy

Freedom in Simplicity
Easy-access
Chamber
User-friendly
menu & buttons
Built-in
connectivity
options
Quiet, integrated
design

Powered by Technology
Auto
algorithm
ThermoSmart™
Expiratory relief
SensAwake™

Engaging Patients
Apple, the Apple logo and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries.
Google Play and the Google Play logo are trademarks of Google Inc.

Empowering Clinicians

The Mask Matters Most

Questions?

Thank you
Fisher & Paykel Healthcare Investor Day
Sydney, October 2017